Join
Live feed
·
PRReleasevia Quantisnow
Entasis Therapeutics Holdings Inc. logo

Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial

ByQuantisnow·Wall Street's wire, on your screen.
ETTX· Entasis Therapeutics Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ETTX (Entasis Therapeutics Holdings Inc.) and more on Quantisnow.